Vectura achieves £9 million royalty cap from GSK Ellipta products
Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.
Vectura Group has announced that, based on the continued strong performance of GSK's Ellipta products reported by GSK in its Q4 2016 results announced on 8 February 2017 and the Group's subsequent receipt of its royalty statement from GSK, it has achieved the £9 million calendar year royalty cap on net sales of these products in 2016, a year earlier than previously guided.
Vectura receives a low single-digit percentage royalty on net sales of GSK's Ellipta products (Breo/Relvar Ellipta, Anoro Ellipta and Incruse Ellipta) under a legacy Skyepharma agreement with GSK, subject to a cap of £9 million per calendar year. The Group will record £5.4 million of this capped amount in its 2016 revenues, representing income since 10 June 2016, the effective date of the merger with Skyepharma.
This is additional to the royalties earned in respect of a separate Vectura legacy agreement with GSK which was subject to a £13 million calendar year cap. This cap was materially achieved before GSK decided not to extend the term of this latter agreement. Accordingly, for the financial year 1 April to 31 December 2016, the Group will record £7.3 million royalties under this legacy agreement.
James Ward-Lilley, CEO, commented: "We are pleased to see continued momentum in Vectura's recurring revenues driven by the strong performance of our partnered marketed respiratory products. The merger with Skyepharma has added to the Group's growing revenue streams and combined with anticipated pipeline and partnered programme developments, Vectura is well positioned to capture a growing share of the evolving respiratory market."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance